Welcome to our dedicated page for Inflarx SEC filings (Ticker: IFRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to InflaRx N.V. (Nasdaq: IFRX) SEC filings, where the company discloses financial results, clinical updates and key corporate information as a foreign private issuer. InflaRx files annual reports on Form 20-F and current reports on Form 6-K that include unaudited condensed consolidated financial statements, management’s discussion and analysis of financial condition and results of operations, and detailed descriptions of clinical and regulatory developments.
Through these filings, readers can review how InflaRx reports progress with its complement-focused pipeline, including the oral C5a receptor inhibitor izicopan (INF904) and the anti-C5a monoclonal antibody vilobelimab. Selected 6-K reports incorporate press releases and presentations on Phase 2a data in hidradenitis suppurativa and chronic spontaneous urticaria, analyses of Phase 3 data in pyoderma gangrenosum, and updates on BARDA-supported studies in acute respiratory distress syndrome.
InflaRx’s SEC filings also document matters such as changes in independent auditors, notices from Nasdaq regarding minimum bid price requirements and subsequent compliance, and information about collaboration arrangements, including royalty-bearing rights related to the anti-C5a antibody BDB-001 in China. Financial sections outline revenues, research and development expenses, sales and marketing costs, general and administrative expenses, cash balances and financing activities.
On Stock Titan, InflaRx filings are updated as new documents are released on EDGAR. AI-powered tools can help summarize lengthy 20-F and 6-K reports, highlight key points about IFRX’s clinical programs, and surface information on risk factors, liquidity and capital resources. Users interested in insider or major shareholder activity can complement these filings with ownership and transaction data where available, while relying on the filings themselves for the company’s official narrative on its complement-system therapeutic strategy and financial position.